Physician profile
Samuel Klein
NPI 1679590186
$295,468.95
in general payments reported to CMS, 2019-2025
23 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $15K · 2021: $25K · 2022: $35K · 2023: $30K · 2024: $73K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $135K · Travel and Lodging: $20K · Food and Beverage: $3,603 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $134,543.67 |
| Travel and Lodging | $20,400.25 |
| Food and Beverage | $3,603.32 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $101,698.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39,860.84 | 2019-2025 | Jardiance |
| Abbvie INC. | $27,063.16 | 2024-2025 | |
| Novo Nordisk INC | $24,735.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Eli Lilly and Company | $24,431.01 | 2022-2024 | |
| Pfizer INC. | $22,301.00 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $20,107.87 | 2022-2024 | |
| Madrigal Pharmaceuticals | $7,808.01 | 2025 | Rezdiffra |
| Janssen Research & Development, LLC | $7,150.00 | 2021 | |
| Boehringer Ingelheim International Gmbh | $5,600.00 | 2025 | |
| Astrazeneca Uk Limited | $4,564.50 | 2025 | |
| Boehringer Ingelheim Mexico Sa De Cv | $3,750.00 | 2019 | |
| Medical Device Business Services, INC. | $2,525.00 | 2020 | |
| Theratechnologies INC. | $2,000.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $1,480.00 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $116.07 | 2021 | |
| Esperion Therapeutics, INC. | $101.51 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $68.24 | 2019 | |
| La Jolla Pharmaceutical Company | $41.75 | 2019 | |
| Becton, Dickinson and Company | $27.61 | 2019 | |
| Amgen INC. | $22.04 | 2024 | |
| Lilly USA, LLC | $16.30 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.